Journal
MOLECULAR BIOLOGY OF THE CELL
Volume 19, Issue 5, Pages 2278-2288Publisher
AMER SOC CELL BIOLOGY
DOI: 10.1091/mbc.E07-10-1068
Keywords
-
Categories
Funding
- Rays of Hope, breast cancer research, BHS
- Baystate Medical Center/University of Massachusetts at Amherst
- Pioneer Valley Life Sciences Institute, Baystate Medical Center/University Massachusetts at Amherst
- Department of Defense
Ask authors/readers for more resources
Signaling pathways engaged by angiogenic factors bFGF and VEGF in tumor angiogenesis are not fully understood. The current study identifies cytoplasmic tyrosine kinase c-Abl as a key factor differentially mediating bFGF- and VEGF-induced angiogenesis in microvascular endothelial cells. STI571, a c-Abl kinase inhibitor, only inhibited bFGF- but not VEGF-induced angiogenesis. bFGF induced membrane receptor cooperation between integrin beta(3) and FGF receptor, and triggered a downstream cascade including FAK, c-Abl, and MAPK. This signaling pathway is different from one utilized by VEGF that includes integrin beta(5), VEGF receptor-2, Src, FAK, and MAPK. Ectopic expression of wild-type c-Abl sensitized angiogenic response to bFGF, but kinase dead mutant c-Abl abolished this activity. Furthermore, the wild-type c-Abl enhanced angiogenesis in both Matrigel implantation and tumor xenograft models. These data provide novel insights into c-Abl's differential functions in mediating bFGF- and VEGF-induced angiogenesis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available